Baird Maintains Neutral on Sage Therapeutics, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and lowers the price target from $15 to $13.
July 25, 2024 | 11:24 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst Joel Beatty maintains a Neutral rating on Sage Therapeutics and lowers the price target from $15 to $13.
The lowered price target from $15 to $13 by Baird suggests a less optimistic outlook for Sage Therapeutics, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100